Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Sunday, Savara Unveils Phase 3 IMPALA-2 Trial Data On Molgramostim For Autoimmune Pulmonary Alveolar Proteinosis At ERS Congress 2024

Author: Benzinga Newsdesk | September 09, 2024 03:45am

Mean Change From Baseline in Disease Severity Score (DSS) Showed Significant Improvement with Molgramostim Compared with Placebo at Weeks 24 and 48
Responder Analysis Results for Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO%) Showed Significantly Higher Proportions of Molgramostim Responders Compared with Placebo at Weeks 24 and 48
Responder Analysis Results for St. George's Respiratory Questionnaire (SGRQ) Total Score Supported Numeric and Significant Improvements with Molgramostim Compared with Placebo at Weeks 24 and 48, Respectively
Ground Glass Opacification (GGO) Score, a Measure of Surfactant Burden, Significantly Improved with Molgramostim Compared with Placebo at Week 24

Posted In: SVRA